CN102858768B - 取代三唑并吡啶 - Google Patents

取代三唑并吡啶 Download PDF

Info

Publication number
CN102858768B
CN102858768B CN201080062548.9A CN201080062548A CN102858768B CN 102858768 B CN102858768 B CN 102858768B CN 201080062548 A CN201080062548 A CN 201080062548A CN 102858768 B CN102858768 B CN 102858768B
Authority
CN
China
Prior art keywords
general formula
compounds
alkyl
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080062548.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858768A (zh
Inventor
V·舒尔策
M·科皮茨
D·科泽蒙德
B·巴德尔
P·利瑙
H·布里姆
S·霍尔顿
G·西迈斯特
S·佩克特
A·M·温内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CN102858768A publication Critical patent/CN102858768A/zh
Application granted granted Critical
Publication of CN102858768B publication Critical patent/CN102858768B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080062548.9A 2009-11-30 2010-11-17 取代三唑并吡啶 Expired - Fee Related CN102858768B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075527.3 2009-11-30
EP09075527A EP2343294A1 (en) 2009-11-30 2009-11-30 Substituted triazolopyridines
PCT/EP2010/006993 WO2011063907A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Publications (2)

Publication Number Publication Date
CN102858768A CN102858768A (zh) 2013-01-02
CN102858768B true CN102858768B (zh) 2016-01-20

Family

ID=42026745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080062548.9A Expired - Fee Related CN102858768B (zh) 2009-11-30 2010-11-17 取代三唑并吡啶

Country Status (7)

Country Link
US (1) US8551980B2 (enExample)
EP (2) EP2343294A1 (enExample)
JP (1) JP5805652B2 (enExample)
CN (1) CN102858768B (enExample)
CA (1) CA2781914A1 (enExample)
ES (1) ES2439776T3 (enExample)
WO (1) WO2011063907A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012080230A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5822944B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
US9212184B2 (en) 2010-12-17 2015-12-15 Bayer Intellectual Property Gmbh 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080236A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2571741T3 (es) 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
CA2832310A1 (en) 2011-04-06 2012-10-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EP2872506A1 (en) 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898249A (zh) * 2003-12-19 2007-01-17 默克公司 有丝分裂驱动蛋白抑制剂
WO2009010530A1 (en) * 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009024824A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009047514A1 (en) * 2007-10-10 2009-04-16 Cancer Research Technology Limited [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
CN101535307A (zh) * 2006-08-30 2009-09-16 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0690447B2 (ja) 1986-09-12 1994-11-14 コニカ株式会社 ハロゲン化銀写真感光材料
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2003000659A1 (en) 2001-06-26 2003-01-03 Nissan Chemical Industries, Ltd. Heterocycloiminophenyl compounds and fungicides and insecticides for agricultural and horticultural use
CA2498004C (en) 2002-09-11 2013-06-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
ATE533497T1 (de) 2005-12-27 2011-12-15 Genentech Inc Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP2468887A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
AU2008291075A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
EA201000797A1 (ru) 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
EP2288260A4 (en) 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
BRPI0922452A2 (pt) 2008-12-19 2015-12-15 Leo Pharma As composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
JP2012517971A (ja) * 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
CA2759939A1 (en) 2009-05-20 2010-11-25 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8481555B2 (en) 2010-04-30 2013-07-09 Bristol-Myers Squibb Company Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898249A (zh) * 2003-12-19 2007-01-17 默克公司 有丝分裂驱动蛋白抑制剂
CN101535307A (zh) * 2006-08-30 2009-09-16 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
WO2009010530A1 (en) * 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009024824A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009047514A1 (en) * 2007-10-10 2009-04-16 Cancer Research Technology Limited [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Small-Molecule Inhibitor of Mps1 Blocks the Spindle-Checkpoint Response to a Lack of Tension on Mitotic Chromosomes;Russell K. Dorer 等;《Current Biology》;20050607;第15卷(第11期);第1070-1076页 *
Aurora Kinase Inhibitor ZM447439 Blocks Chromosomeinduced Spindle Assembly, the Completion of Chromosome Condensation, and the Establishment of the Spindle Integrity Checkpoint in Xenopus Egg Extracts;Bedrick B. Gadea 等;《Molecular Biology of the Cell》;20041222;第16卷(第3期);第1305-1318页 *
Aurora-kinase inhibitors as anticancer agents;Nicholas Keen 等;《Nat Rev Cancer》;20041231;第4卷(第12期);第927-936页 *
纺锤体驱动蛋白抑制剂的设计、合成与生物活性研究;阮秀琴 等;《化学学报》;20080731;第66卷(第14期);第1731-1734页 *

Also Published As

Publication number Publication date
HK1180333A1 (zh) 2013-10-18
WO2011063907A1 (en) 2011-06-03
JP5805652B2 (ja) 2015-11-04
EP2343294A1 (en) 2011-07-13
US8551980B2 (en) 2013-10-08
JP2013512263A (ja) 2013-04-11
CN102858768A (zh) 2013-01-02
EP2507233A1 (en) 2012-10-10
ES2439776T3 (es) 2014-01-24
CA2781914A1 (en) 2011-06-03
EP2507233B1 (en) 2013-11-06
US20120328611A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
CN102858768B (zh) 取代三唑并吡啶
JP5805653B2 (ja) トリアゾロピリジン
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN103687858B (zh) 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
JP6168773B2 (ja) 置換イミダゾキノキサリン
JP5841078B2 (ja) イミダゾピラジン
JP5822944B2 (ja) 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
JP5805654B2 (ja) トリアゾロピリジン誘導体
TWI558703B (zh) 三唑并吡啶
CN103429592A (zh) 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
JP5951750B2 (ja) 置換イミダゾピリジン類およびその中間体
CN102596932A (zh) 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
JP2014517053A (ja) ヘテロシクリルアミノイミダゾピリダジン
CN103415518A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CN103403006B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
HK1180333B (en) Substituted triazolopyridines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180333

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1180333

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20171117

CF01 Termination of patent right due to non-payment of annual fee